Calimmune Initiates HIV Stem Cell Study at Two California Research Sites
7/9/2013 12:01:49 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection,” utilizes a gene medicine called Cal-1, developed in the lab of Nobel Laureate Dr. David Baltimore and by Calimmune.
Help employers find you! Check out all the jobs and post your resume.